A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Latest Information Update: 04 Mar 2026
At a glance
- Drugs NS 863 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors NS Pharma
Most Recent Events
- 04 Mar 2026 New trial record